跳至主要内容
临床试验/ISRCTN13477304
ISRCTN13477304进行中(未招募)未知

PAINSTORM: Partnership for Assessment and Investigation of NeuP: Studies Tracking Outcomes, Risks and Mechanisms

niversity of Dundee0 个研究点目标入组 200 人开始时间: 2022年11月15日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. 18 years or older
  • 2. Planned course of potentially neurotoxic chemotherapy for the treatment of cancer. This includes the following:
  • 2.1. Platinum drugs
  • 2.2. Taxanes
  • 2.3. Vinca alkaloids
  • 2.4. Epothilones
  • 2.5. Proteasome inhibitors
  • 2.6. Thalidomide
  • 2.7. Vedotin-based drugs
  • 2.8. Checkpoint inhibitors

排除标准

  • 1. Incapacity to give consent or to complete the study questionnaires due to insufficient language command or mental deficiencies, in the opinion of the investigator.
  • 2. Functional impairment - ECOG Performance Status Scale great than or equal to 3 at baseline.
  • 3. Concurrent clinically defined severe physical or psychiatric disorders that would preclude accurate phenotyping.
  • 4. Moderate to severe pain from other causes that may confound assessment or reporting of pain if unable to differentiate from CIPN.
  • 5. Patients who are in the opinion of the investigator, or treating oncology team, unsuitable for participation in the study.

研究者

发起方
niversity of Dundee

相似试验